Elena Vásquez Garcia – Pancreatic Cancer Remission
Background
Elena Vásquez García is a 42-year-old accountant from Trujillo, Peru, who had resided in Brazil for many years. In December 2024, she was diagnosed with pancreatic adenocarcinoma — a condition widely recognized in oncology as one of the most lethal malignancies, with a 5-year survival rate of approximately 12%.
Elena approached her diagnosis with the analytical mindset of her profession: seeking precise strategy, real data, and impeccable execution. Rather than accepting the conventional prognosis, she sought out an integrative oncology team led by Dr. Jackelin Laza and committed to an intensive year-long protocol beginning in early 2025.
Clinical Evidence
Baseline (December 2024 / January 2025)
- Tumor Marker (CA 19-9): 1,250 U/mL — indicating high-intensity active oncological process
- CT Imaging: Massive bilateral cystic masses identified in the pancreatic region
- Clinical Status: Advanced pancreatic adenocarcinoma
Follow-up (January 2026)
- Tumor Marker (CA 19-9): 12 U/mL — within normal reference range (0–37 U/mL)
- CT Imaging: Complete resolution of cystic masses — no residual lesions
- Clinical Status: Full remission — no evidence of cancer
Protocol Applied
The treatment protocol spanned an intensive 12-month period and included the following components:
- Zeolite Detoxification: Heavy metal and toxin removal using clinoptilolite zeolite
- Seawater Remineralization (Quinton): Marine-derived mineral restoration for cellular electrolyte balance
- CDS Protocol (Chlorine Dioxide Solution): Systemic application for cellular oxygenation and pathogen elimination
- Intravenous Applications: High-dose vitamin C and other IV nutrients per Riordan protocol adaptations
- Chlorophyll Extract with Mother Cells: Plant-based stem cell support for tissue regeneration
- Biological Capsules and Orthomolecular Therapy: Targeted nutrient therapy at pharmacological doses
The protocol was supervised by Dr. Jackelin Laza, who provided both clinical expertise and psychological support throughout the treatment course.
Results
At the start of 2026, medical examinations and tumor markers demonstrated complete remission:
- No trace of cancer detected
- Tumor marker (CA 19-9) normalized from 1,250 to 12 U/mL (99.04% reduction)
- CT imaging confirmed complete resolution of all cystic masses
- Full physiological equilibrium restored
Why This Case Matters
Pancreatic adenocarcinoma remains one of the most challenging malignancies in oncology, with conventional 5-year survival rates below 12%. This case demonstrates that an aggressive integrative approach — combining detoxification, nutritional immunology, and targeted protocols — can achieve complete remission in cases that conventional medicine often considers terminal.
The transformation of CA 19-9 from 1,250 U/mL to 12 U/mL represents not merely improvement but complete normalization. The radiological confirmation of mass resolution validates that this was not biochemical response alone but anatomical cure.
This case challenges the conventional oncology paradigm and suggests that integrative protocols warrant serious clinical investigation as primary or adjunctive treatment for pancreatic cancer.
Source
Patient testimony, February 2026. Published with patient consent.